文献速递创伤与烧伤心脑血管急症

疑似创伤性脑损伤且无休克、头部CT正常者中氨甲环酸不良事件不劣于安慰剂:一项随机试验的回顾性研究

Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial.
PubMed 文献 · J Trauma Acute Care Surg · 2022-03-28
一句话结论疑似TBI且初始CT无ICH者,2g氨甲环酸团注或1g团注+1g 8小时输注未增加不良事件或不良结局;作者认为因2g团注有死亡率获益,疑似TBI应给予。

本研究基于2015至2017年一项多中心随机试验的数据,分析966例中395例初始CT无颅内出血的疑似TBI患者,比较2g氨甲环酸团注、1g团注+1g 8小时输注与安慰剂的不良事件(28天发生率)及不良结局。结果显示两种氨甲环酸方案与安慰剂相比,均未发现不良事件或不良结局的统计学显著增加;除1g团注+1g输注组两种受伤机制人数偏多外,人口学与损伤评分无统计学差异。作者结论认为在疑似TBI无颅内出血者中给予氨甲环酸不增加不良事件或不良结局,且因院前2g团注与死亡率获益相关,应在疑似TBI中给予。证据等级为治疗/护理管理Level II。

要点

  • 疑似TBI且初始CT无颅内出血者中,2g氨甲环酸团注或1g团注+1g 8小时输注与安慰剂相比,不良事件或不良结局均无统计学显著增加。
  • 研究分析15项28天不良事件(心肌梗死、深静脉血栓、癫痫发作、肺栓塞、急性呼吸窘迫综合征、心力衰竭、肝衰竭、肾衰竭、脑血管意外、心脏骤停、脑血管痉挛、任何血栓栓塞、高钠血症、急性肾损伤、感染)。
  • 其他不良结局包括28天和6个月死亡率、出院和6个月Glasgow结局量表扩展评分≤4、无ICU天数、无呼吸机天数、无住院天数及联合不良结局。
  • 除1g氨甲环酸团注+1g输注组两种受伤机制人数偏多外,各组人口学与损伤评分无统计学差异。
  • 作者认为,因院前2g团注与死亡率获益相关,应在疑似TBI中给予氨甲环酸。

适用人群与场景

  • 疑似创伤性脑损伤且初始头部CT无颅内出血的患者;来自2015至2017年多中心随机试验中966例受试者里的395例。
  • 原试验研究氨甲环酸对中重度TBI的效果,给药场景为院前。

处置流程与药物剂量

  • 2g氨甲环酸团注(院前给药)。
  • 1g氨甲环酸团注+1g氨甲环酸8小时输注。
  • 安慰剂团注+安慰剂输注。

研究设计与关键结果

  • 研究类型:一项2015至2017年多中心随机试验的回顾性研究;纳入966例受试者中395例初始CT无颅内出血者。
  • 干预与对照:2g氨甲环酸团注、1g团注+1g 8小时输注、安慰剂团注+安慰剂输注。
  • 主要结果:两种氨甲环酸方案与安慰剂相比,15项28天不良事件及不良结局均无统计学显著增加。
  • 其他不良结局:28天和6个月死亡率、出院和6个月Glasgow结局量表扩展评分≤4、无ICU天数、无呼吸机天数、无住院天数及联合不良结局,均无统计学显著增加。
  • 基线:除1g氨甲环酸团注+1g输注组两种受伤机制人数偏多外,人口学与损伤评分无统计学差异。

证据类型、等级与局限

  • 证据类型:随机试验的回顾性研究;证据等级:治疗/护理管理Level II。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在疑似TBI且初始CT无颅内出血者中,使用2g氨甲环酸团注或1g团注+1g 8小时输注未观察到不良事件或不良结局增加。
  • 作者认为,因院前2g团注与死亡率获益相关,应在疑似TBI中给予氨甲环酸。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A 2-g bolus of tranexamic acid (TXA) has been shown to reduce 28-day mortality in a randomized controlled trial. This study investigates whether out-of-hospital TXA use is associated with adverse events or unfavorable outcomes in suspected traumatic brain injury (TBI) when intracranial hemorrhage (ICH) is absent on initial computed tomography.

METHODS: This study used data from a 2015 to 2017, multicenter, randomized trial studying the effect of the following TXA doses on moderate to severe TBI: 2-g bolus, 1-g bolus plus 1-g infusion over 8 hours, and a placebo bolus with placebo infusion. Of the 966 participants enrolled, 395 with an initial computed tomography negative for ICH were included in this analysis. Fifteen adverse events (28-day incidence) were studied: myocardial infarction, deep vein thrombosis, seizure, pulmonary embolism, acute respiratory distress syndrome, cardiac failure, liver failure, renal failure, cerebrovascular accident, cardiac arrest, cerebral vasospasm, "any thromboembolism," hypernatremia, acute kidney injury, and infection. Other unfavorable outcomes analyzed include mortality at 28 days and 6 months, Glasgow Outcome Scale-Extended score of ≤4 at discharge and 6 months, intensive care unit-free days, ventilator-free days, hospital-free days, and combined unfavorable outcomes. In both study drug groups, the incidence of dichotomous outcomes and quantity of ordinal outcomes were compared with placebo.

RESULTS: No statistically significant increase in adverse events or unfavorable outcomes was found between either TXA dosing regimen and placebo. Demographics and injury scores were not statistically different other than two methods of injury, which were overrepresented in the 1-g TXA bolus plus 1-g TXA infusion.

CONCLUSION: Administration of either a 2-g TXA bolus or a 1-g TXA bolus plus 1-g TXA 8-hour infusion in suspected TBIs without ICH is not associated with increased adverse events or unfavorable outcomes. Because the out-of-hospital 2-g bolus is associated with a mortality benefit, it should be administered in suspected TBI.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Harmer JW, Dewey EN, Meier EN, et al. Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial. J Trauma Acute Care Surg. 2022. PMID: 35358154. doi:10.1097/TA.0000000000003635

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。